Sign In
Buy APTO
$1.71
+0 (+0%)
At Close: Jul 25, 2025
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
04:00pm, Thursday, 09'th Jan 2025
SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announ
Aptose Announces Positive Decision by Nasdaq Hearings Panel
04:05pm, Thursday, 19'th Dec 2024
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. Sites TUS and TUS+VEN Broadly Active Across AML Populations, with Favorable Safety TUS-based therapies are a
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
07:30am, Tuesday, 03'rd Dec 2024
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
04:15pm, Monday, 25'th Nov 2024
SAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hi
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
08:00am, Friday, 22'nd Nov 2024
SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hi
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
07:30am, Wednesday, 20'th Nov 2024
TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and az
Aptose Reports Results for the Third Quarter 2024
04:01pm, Friday, 08'th Nov 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tus
Aptose Announces Results from Special Meeting of Shareholders
04:15pm, Thursday, 05'th Sep 2024
SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing t
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
04:30pm, Thursday, 15'th Aug 2024
SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hi
Aptose Reports Results for the Second Quarter 2024
05:06pm, Thursday, 08'th Aug 2024
TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy
Aptose Announces Receipt of Deficiency Notice from Nasdaq
05:00pm, Friday, 19'th Jul 2024
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hi
Aptose Announces Results from Annual and Special Meeting of Shareholders
05:30pm, Tuesday, 18'th Jun 2024
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hi
